Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Publication date: Available online 15 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis, Yehuda Handelsman, Armando Lira Pineda, Narimon Honarpour, Anthony C Keech, Peter S Sever, Terje R Pedersen Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated ...
Source: The Lancet Diabetes and Endocrinology - September 16, 2017 Category: Endocrinology Source Type: research

PCSK9 inhibition and type 2 diabetes
Publication date: Available online 15 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Luca A Lotta, Simon J Griffin (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - September 16, 2017 Category: Endocrinology Source Type: research

Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications
Publication date: Available online 14 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Mark O Goodarzi Genome-wide association studies (GWAS) for BMI, waist-to-hip ratio, and other adiposity traits have identified more than 300 single-nucleotide polymorphisms (SNPs). Although there is reason to hope that these discoveries will eventually lead to new preventive and therapeutic agents for obesity, this will take time because such developments require detailed mechanistic understanding of how an SNP influences phenotype (and this information is largely unavailable). Fortunately, absence of functio...
Source: The Lancet Diabetes and Endocrinology - September 15, 2017 Category: Endocrinology Source Type: research

Metabolically healthy obesity: the low-hanging fruit in obesity treatment?
Publication date: Available online 14 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Norbert Stefan, Hans-Ulrich Häring, Matthias B Schulze Obesity increases the risk of several other chronic diseases and, because of its epidemic proportions, has become a major public health problem worldwide. Alarmingly, a lower proportion of adults have tried to lose weight during the past decade than during the mid-1980s to 1990s. The first-line treatment option for obesity is lifestyle intervention. Although this approach can decrease fat mass in the short term, these beneficial effects typically do ...
Source: The Lancet Diabetes and Endocrinology - September 15, 2017 Category: Endocrinology Source Type: research

Progress and challenges in anti-obesity pharmacotherapy
Publication date: Available online 14 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Daniel H Bessesen, Luc F Van Gaal Obesity is a serious and growing worldwide health challenge. Healthy lifestyle choices are the foundation of obesity treatment. However, weight loss can lead to physiological adaptations that promote weight regain. As a result, lifestyle treatment alone typically produces only modest weight loss that is difficult to sustain. In other metabolic diseases, pharmacotherapy is an accepted adjunct to lifestyle. Several anti-obesity drugs have been approved in the USA, European Unio...
Source: The Lancet Diabetes and Endocrinology - September 15, 2017 Category: Endocrinology Source Type: research

Precision medicine: diagnosis and management of obesity
Publication date: Available online 14 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Gema Frühbeck, Dimitrios N Kiortsis, Victoria Catalán (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - September 15, 2017 Category: Endocrinology Source Type: research

SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
Publication date: Available online 14 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): John R Petrie (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - September 15, 2017 Category: Endocrinology Source Type: research

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
This study was registered with ClinicalTrials.gov, number NCT02268214; data collection for the present analysis was completed on Jan 4, 2017, and a 28 week extension phase is ongoing. Findings Between Nov 11, 2014, and April 16, 2016, 833 patients were assigned to treatment groups and included in safety analyses (dapagliflozin 5 mg [n=277] vs dapagliflozin 10 mg [n=296] vs placebo [n=260]; 778 of these patients were randomly assigned and included in the full analysis set for efficacy analyses (259 vs 259 vs 260; difference due to randomisation error affecting 55 patients). Mean baseline HbA1c was 8·53% (70 mmol/mol;...
Source: The Lancet Diabetes and Endocrinology - September 15, 2017 Category: Endocrinology Source Type: research

Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs
Publication date: Available online 13 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Vivian A Fonseca, Dragana Lovre (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
This study is registered with ClinicalTrials.gov, number NCT00700856. Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 ...
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
Publication date: Available online 13 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan Background The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolera...
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

Break point instead of ACE: acarbose, post-load glycaemic excursions, and cardiovascular events
Publication date: Available online 13 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Michael A Nauck, Juris J Meier (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

South Asian floods and Hurricane Harvey: diabetes in crisis
Publication date: Available online 6 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - September 7, 2017 Category: Endocrinology Source Type: research

Distal technologies and type 1 diabetes management
Publication date: Available online 31 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Danny C Duke, Samantha Barry, David V Wagner, Jane Speight, Pratik Choudhary, Michael A Harris Type 1 diabetes requires intensive self-management to avoid acute and long-term health complications. In the past two decades, substantial advances in technology have enabled more effective and convenient self-management of type 1 diabetes. Although proximal technologies (eg, insulin pumps, continuous glucose monitors, closed-loop and artificial pancreas systems) have been the subject of frequent systematic and narrati...
Source: The Lancet Diabetes and Endocrinology - September 1, 2017 Category: Endocrinology Source Type: research

Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study
Publication date: Available online 30 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Sofia Dahlqvist, Annika Rosengren, Soffia Gudbjörnsdottir, Aldina Pivodic, Hans Wedel, Mikhail Kosiborod, Ann-Marie Svensson, Marcus Lind Background Type 1 diabetes is associated with an increased risk of developing several cardiovascular complications. To our knowledge, the independent association between type 1 diabetes and atrial fibrillation has not been studied. Methods We did a prospective case-control study of individuals with type 1 diabetes in the Swedish National Diabetes Registry who were each ma...
Source: The Lancet Diabetes and Endocrinology - August 30, 2017 Category: Endocrinology Source Type: research

Is atrial fibrillation another manifestation of organ damage in diabetes?
Publication date: Available online 30 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kazuo Miyazawa, Gregory Y H Lip (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 30, 2017 Category: Endocrinology Source Type: research

Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study
In this study, we investigated the effect of dietary nutrients on blood lipids and blood pressure, two of the most important risk factors for cardiovascular disease, in low-income, middle-income, and high-income countries. Methods We studied 125 287 participants from 18 countries in North America, South America, Europe, Africa, and Asia in the Prospective Urban Rural Epidemiology (PURE) study. Habitual food intake was measured with validated food frequency questionnaires. We assessed the associations between nutrients (total fats, saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids, carbohydra...
Source: The Lancet Diabetes and Endocrinology - August 29, 2017 Category: Endocrinology Source Type: research

Macronutrients and cardiovascular risk in a global context
Publication date: Available online 29 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Nita G Forouhi, Naveed Sattar, Fumiaki Imamura (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 29, 2017 Category: Endocrinology Source Type: research

Type 2 diabetes in adolescents and young adults
Publication date: Available online 25 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Nadia Lascar, James Brown, Helen Pattison, Anthony H Barnett, Clifford J Bailey, Srikanth Bellary The prevalence of type 2 diabetes in adolescents and young adults is dramatically increasing. Similar to older-onset type 2 diabetes, the major predisposing risk factors are obesity, family history, and sedentary lifestyle. Onset of diabetes at a younger age (defined here as up to age 40 years) is associated with longer disease exposure and increased risk for chronic complications. Young-onset type 2 diabetes also a...
Source: The Lancet Diabetes and Endocrinology - August 26, 2017 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2017; 5: 524 –33
Publication date: September 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 9 (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 26, 2017 Category: Endocrinology Source Type: research

Meta-analysis of artificial pancreas trials: methodological considerations – Authors' reply
Publication date: September 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 9 Author(s): Alanna Weisman, Caroline K Kramer, Bruce A Perkins (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 26, 2017 Category: Endocrinology Source Type: research

Meta-analysis of artificial pancreas trials: methodological considerations
Publication date: September 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 9 Author(s): Eleni Bekiari, Thomas Karagiannis, Anna-Bettina Haidich, Apostolos Tsapas (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 26, 2017 Category: Endocrinology Source Type: research

Issues with European guidelines for phenylketonuria – Authors' reply
Publication date: September 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 9 Author(s): Francjan J van Spronsen, Annemiek M J van Wegberg, Kirsten Ahring, Amaya Bélanger-Quintana, Nenad Blau, Annet M Bosch, Alberto Burlina, Jaime Campistol, Francois Feillet, Maria Giżewska, Stephan C Huijbregts, Shauna Kearney, Vincenzo Leuzzi, Francois Maillot, Ania C Muntau, Fritz K Trefz, Margreet van Rijn, Anita MacDonald (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 26, 2017 Category: Endocrinology Source Type: research

Issues with European guidelines for phenylketonuria
Publication date: September 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 9 Author(s): Peter Burgard, Kurt Ullrich, Diana Ballhausen, Julia B Hennermann, Carla E M Hollak, Mirjam Langeveld, Daniela Karall, Vassiliki Konstantopoulou, Esther M Maier, Frauke Lang, Robin Lachmann, Elaine Murphy, Sven Garbade, Georg F Hoffmann, Stefan Kölker, Martin Lindner, Johannes Zschocke (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 26, 2017 Category: Endocrinology Source Type: research

A UK Civil Aviation Authority protocol to allow pilots with insulin-treated diabetes to fly commercial aircraft
Publication date: September 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 9 Author(s): Stuart J Mitchell, Julia Hine, Jill Vening, Joanne Montague, Sally Evans, Ken M Shaw, Brian M Frier, Simon R Heller, David L Russell-Jones (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 26, 2017 Category: Endocrinology Source Type: research

Aiding sleep in type 2 diabetes: therapeutic considerations
Publication date: Available online 24 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Xiao Tan, Lieve van Egmond, Colin D Chapman, Jonathan Cedernaes, Christian Benedict Insomnia and obstructive sleep apnoea (OSA) are more prevalent in patients with type 2 diabetes than in the general population. Both insomnia and OSA have been linked to cardiometabolic alterations (eg, hypertension, increased activity of the sympathetic nervous system, and systemic insulin resistance) that can exacerbate the pathophysiology of type 2 diabetes. Improvement of sleep in patients with diabetes could therefore aid th...
Source: The Lancet Diabetes and Endocrinology - August 25, 2017 Category: Endocrinology Source Type: research

Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials
Publication date: Available online 10 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Sanjay Basu, Jeremy B Sussman, Seth A Berkowitz, Rodney A Hayward, John S Yudkin Background In view of substantial mis-estimation of risks of diabetes complications using existing equations, we sought to develop updated Risk Equations for Complications Of type 2 Diabetes (RECODe). Methods To develop and validate these risk equations, we used data from the Action to Control Cardiovascular Risk in Diabetes study (ACCORD, n=9635; 2001–09) and validated the equations for microvascular events using data from th...
Source: The Lancet Diabetes and Endocrinology - August 11, 2017 Category: Endocrinology Source Type: research

New risk equations for complications of type 2 diabetes are welcome, but a broader perspective is needed
Publication date: Available online 10 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Coen D A Stehouwer (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 11, 2017 Category: Endocrinology Source Type: research

Research digest: more cardiovascular outcome trials in diabetes
Publication date: Available online 9 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Naveed Sattar, David Preiss (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 10, 2017 Category: Endocrinology Source Type: research

Glucose-lowering drugs: balancing risks and benefits
Publication date: Available online 9 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 10, 2017 Category: Endocrinology Source Type: research

How to address non-communicable diseases in urban Africa
Publication date: Available online 7 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Jo Hunter-Adams, Blaise Nguendo Yongsi, Kafui Dzasi, Susan Parnell, Jo Ivey Boufford, Edgar Pieterse, Tolu Oni (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 8, 2017 Category: Endocrinology Source Type: research

Renal trials in diabetes need a platform: time for a global approach?
Publication date: Available online 7 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Dick de Zeeuw, Hiddo J L Heerspink, Meg Jardine, Vlado Perkovic (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 8, 2017 Category: Endocrinology Source Type: research

The emotional journey of gestational diabetes
Publication date: Available online 4 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Ciara Feighan, Hilary Devine, Usha Daniel, Mensud Hatunic, Mary Frances Higgins (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 5, 2017 Category: Endocrinology Source Type: research

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed ...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

SGLT2 inhibitors in the real world: too good to be true?
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): David Fitchett (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

Prediabetes: moving away from a glucocentric definition
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Prashanth R J Vas, K George Alberti, Michael E Edmonds (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System
Publication date: Available online 18 July 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Gian Paolo Fadini, Angelo Avogaro (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2017; 5: 569 –71
Publication date: August 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 8 (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2017; 5: 597 –609
Publication date: August 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 8 (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research

Absorbing metabolic illness in India
Publication date: August 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 8 Author(s): Emily Yates-Doerr (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research

Oldest case of gigantism? Assessment of the alleged remains of Sa-Nakht, king of ancient Egypt
Publication date: August 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 8 Author(s): Francesco M Galassi, Maciej Henneberg, Wouter de Herder, Frank Rühli, Michael E Habicht (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research

Microvascular outcomes in type 2 diabetes – Authors' reply
Publication date: August 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 8 Author(s): Sophia Zoungas, Hertzel C Gerstein, Rury R Holman, Peter Reaven, Mark Woodward, Hisatomi Arima, Ruth L Coleman, John Chalmers (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research

Microvascular outcomes in type 2 diabetes
Publication date: August 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 8 Author(s): Coen D A Stehouwer, Thomas T van Sloten (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research

Hyperglycaemia in pregnancy: time to ask the hard questions?
Publication date: August 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 8 Author(s): Uma Ram, Suresh Seshadri, Ponnusamy Saravanan (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research

Forging paths to improve diabetes care in low-income settings
Publication date: August 2017 Source:The Lancet Diabetes & Endocrinology, Volume 5, Issue 8 Author(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 19, 2017 Category: Endocrinology Source Type: research

Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data
Publication date: Available online 14 July 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kunihiro Matsushita, Shoshana H Ballew, Josef Coresh, Hisatomi Arima, Johan Ärnlöv, Massimo Cirillo, Natalie Ebert, Jade S Hiramoto, Heejin Kimm, Michael G Shlipak, Frank L J Visseren, Ron T Gansevoort, Csaba P Kovesdy, Varda Shalev, Mark Woodward, Florian Kronenberg Background Some evidence suggests that chronic kidney disease is a risk factor for lower-extremity peripheral artery disease. We aimed to quantify the independent and joint associations of two measures of chronic kidney disease (estimated gl...
Source: The Lancet Diabetes and Endocrinology - July 15, 2017 Category: Endocrinology Source Type: research

Common measures of chronic kidney disease improve vascular risk prediction
Publication date: Available online 14 July 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Austin G Stack (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 15, 2017 Category: Endocrinology Source Type: research

Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial
This study is registered with ClinicalTrials.gov, number NCT02282397. Findings Between April 14, 2015, and May 5, 2016, 37 participants were randomly assigned to the CGM plus CSII group and 38 participants were randomly assigned to the CGM plus MDI group. The study was completed by 36 (97%) of 37 participants in the CGM plus CSII group and 35 (92%) of 38 participants in the CGM plus MDI group. Mean CGM use was 6·7 days per week (SD 0·8) in the CGM plus CSII group and 6·9 days per week (0·3) in the CGM plus MDI group (p=0·86). No participants in the CGM plus CSII group who completed the tr...
Source: The Lancet Diabetes and Endocrinology - July 13, 2017 Category: Endocrinology Source Type: research

Looking again at the Look AHEAD study
Publication date: Available online 12 July 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Edward W Gregg, Rena Wing (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 13, 2017 Category: Endocrinology Source Type: research

Sensor mightier than pump —the jury is still out
Publication date: Available online 12 July 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Roman Hovorka (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - July 13, 2017 Category: Endocrinology Source Type: research